论文部分内容阅读
高血压是世界范围内流行的疾病,原发性高血压病因未明,因此高血压治疗的目标也是血压控制和靶器官保护。高血压降压的个体化差异较大,且目前五大类降压药均为一线药物,为临床选择降压药带来困难。以血浆肾素活性(PRA)为依据将高血压分型,有利于指导临床医师合理选择降压药,增加高血压患者的依从性和降压达标率。现将PRA与降压药物选择的研究予以综述。
Hypertension is a worldwide prevalent disease and the etiology of essential hypertension is unknown, so the goal of treatment for hypertension is also blood pressure control and target organ protection. High blood pressure and individualized large differences, and the current five categories of antihypertensive drugs are first-line drugs, for the clinical choice of antihypertensive drugs difficult. Based on the plasma renin activity (PRA) as the basis for the classification of hypertension, is conducive to guide clinicians to choose a reasonable antihypertensive drugs, increased compliance and antihypertensive patients hypertensive compliance rate. Now PRA and antihypertensive drug selection are reviewed.